• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans

Photo

Intermittent Senolytic Treatment with Dasatinib and Quercetin Produces Benefits in Non-Human Primates


  • Please log in to reply
No replies to this topic

#1 reason

  • Guardian Reason
  • 1,101 posts
  • 241
  • Location:US

Posted 09 June 2023 - 10:22 AM


Researchers here report on the outcome of six months of monthly senolytic therapy in cynomolgus macaques. The results are broadly positive, as one might expect from the established human data. Dasatinib is a chemotherapeutic drug, but senolytic dosing is not sustained as is the case in the treatment of cancer, and side-effects are much reduced as a result. It remains to be seen as to what the optimal dose and dose schedule for this treatment will be. Researchers are trying a range of options, and arguably the human trials conducted by the Mayo Clinic are using too low a dose. Time will tell, but there is a need for more clinical trials, and an opportunity for philanthropists to step in and run few-hundred individual, affordable, safe clinical trials of this cheap senolytic treatment to provide support for physicians to use the therapy off-label for many age-related conditions.

Cellular senescence increases with aging and results in secretion of pro-inflammatory factors that induce local and systemic tissue dysfunction. We conducted the first preclinical trial in a relevant middle-aged nonhuman primate (NHP) model to allow estimation of the main translatable effects of the senolytic combination dasatinib (D) and quercetin (Q), with and without caloric restriction (CR). A multi-systemic survey of age-related changes, including those on immune cells, adipose tissue, the microbiome, and biomarkers of systemic organ and metabolic health are reported.

Age-, weight-, sex-, and glycemic control-matched NHPs (D + Q, n = 9; vehicle [VEH] n = 7) received two consecutive days of D + Q (5 mg/kg + 50 mg/kg) monthly for 6 months, where in month six, a 10% CR was implemented in both D + Q and VEH NHPs to induce equal weight reductions. D + Q reduced senescence marker gene expressions in adipose tissue and circulating PAI-1 and MMP-9. Improvements were observed in immune cell types with significant anti-inflammatory shifts and reductions in microbial translocation biomarkers, despite stable microbiomes. Blood urea nitrogen showed robust improvements with D + Q. CR resulted in significant positive body composition changes in both groups with further improvement in immune cell profiles and decreased GDF15, and the interaction of D + Q and CR dramatically reduced glycosylated hemoglobin A1c.

This work indicates that 6 months of intermittent D + Q exposure is safe and may combat inflammaging via immune benefits and improved intestinal barrier function. We also saw renal benefits, and with CR, improved metabolic health. These data are intended to provide direction for the design of larger controlled intervention trials in older patients.

Link: https://doi.org/10.1...357-023-00830-5


View the full article at FightAging




0 user(s) are reading this topic

0 members, 0 guests, 0 anonymous users